In early January 2026, Natera announced a collaboration with Exelixis on the planned Exelixis-sponsored STELLAR-316 phase 3 ...
Advancing icovamenib toward late-stage clinical development in two Phase II clinical trials in patients with insulin-deficient type 2 diabetes (“T2D”) and in T2D patients currently failing ...
This year’s report highlights the remarkable rise of East Asian cities and the stagnation of several Western cities, showing how global challenges, such as geopolitical tensions and regional ...
What should investors be looking for when it comes to choosing the best dividend stocks to buy today? At Morningstar, we think that the best dividend stocks aren’t simply the highest dividend stocks ...